Sunday, July 24, 2022 1:33:12 PM
The oral mucosa does have less surface area than the sigmoid colon ;so based on surface area brilacidin's absorption should be higher through the colon.
The dosage is in the ulcerative colitis study was 200mg while in the oral mucositis study it was only 3mmg per 5cc.So the absorption should be higher in the UC study
In addition the UC patients were given Brilacidin as a retention enema as opposed to the swish and spit BOM study. The time of contact to the mucosa would be much higher in the UC study.
Yet the UC study showed almost no systemic absorption, nanograms.
Just a reminder 1 billion nanograms are in a gram
" Brilacidin was generally well-tolerated and patients maintained stable normal vital signs during treatment..
Measurements of drug concentrations in plasma continued to show limited systemic absorption of Brilacidin, with all values registering less than 100 ng/mL for all six patients in Cohort A and averaging approximately 200 ng/mL maximum concentrations... "
https://www.globenewswire.com/news-release/2017/03/08/933305/0/en/Cellceutix-Releases-Preliminary-Efficacy-and-Safety-Data-in-Interim-Analysis-of-First-Two-Cohorts-in-Phase-2-Trial-of-Brilacidin-for-the-Induction-of-Remission-of-Mild-to-Moderate-.html
When a company is doing its due diligence to partner with IPIX , do you think they will look at actual numbers ?
Indeed !
GLTA,Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM